Nov 21 2019

Gilead sciences stock

Gilead sciences stock-Gilead sciences stock
Gilead sciences stock-GILD | Complete Gilead Sciences Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Gilead Sciences Inc.

Close Chg Chg %
$62.90 -0.40 -0.63% -0.40 -0.63%

Your Watchlist

Customize MarketWatch

Have Watchlists? Log in to see them here or sign up to get started.

No Items in Watchlist

There are currently no items in this Watchlist.

No Saved Watchlists

Create a list of the investments you want to track.

Something went wrong while loading Watchlist.

Recently Viewed Tickers

No Recent Tickers

Visit a quote page and your recently viewed tickers will be displayed here.

  • Open $63.57
  • Day Range 62.57 – 63.92
  • 52 Week Range 60.32 – 79.61
  • Market Cap $79.66B
  • Shares Outstanding 1.27B
  • Public Float 1.26B
  • Beta 1.01
  • Rev. per Employee $2.02M
  • P/E Ratio 13.62
  • EPS $4.62
  • Yield 4.01%
  • Div >$0.63
  • Ex-Div >Sep 12, 2019
  • Short Interest 14.66M 09/13/19
  • % of Float Shorted 1.16%
  • Average Volume 6.13M


5 Day
  • -5.30%
1 Month
  • -1.01%
3 Month
  • -6.90%
  • 0.56%
1 Year
  • -18.53%

Recent News

  • MarketWatch
  • WSJ

Biotech Funds Are a Belt-And-Suspenders Play on a Volatile Industry

Investors have fled biotech funds in recent years, but it might be time for some bargain hunting. Five funds to consider

  • Sep. 28, 2019 at 11:02 a.m. ET
  • by Barron’s

Our Roundtable Experts Pick 15 Biotech Stocks

As medical breakthroughs lead to revolutionary cures, the future looks bright for patients—and patient investors.

  • Sep. 27, 2019 at 9:39 p.m. ET
  • by Barron’s

Why Bernie is wrong about billionaires

  • Sep. 27, 2019 at 12:31 p.m. ET
  • by Tim Mullaney

Financing Global Health

Impact investing has started to fund the development of drugs to treat neglected diseases, but a vast gap remains

  • Sep. 23, 2019 at 9:00 a.m. ET
  • by Barron’s

Value investing isn’t back — but economic growth is

  • Sep. 20, 2019 at 9:03 a.m. ET
  • by Michael Brush

A Cheap Biotech Is Testing a Novel Treatment for Multiple Sclerosis

Researchers reported that Atara Biotherapeutics treatment showed hints of actually improving the condition of MS patients, instead of just slowing the disease like most available treatments.

  • Sep. 13, 2019 at 8:29 a.m. ET
  • by Barron’s

25 dividend stocks selected for value by an outperforming money manager

  • Aug. 26, 2019 at 1:44 p.m. ET
  • by Philip van Doorn

Bristol-Meyers Deal for Celgene Moves Ahead

Biotech company Amgen said Monday it would buy the rights to the psoriasis drug Otezla from Celgene for $13.4 billion. That will allow Bristol-Myers Squibb to move forward with its merger with Celgene.

  • Aug. 26, 2019 at 9:14 a.m. ET
  • by Barron’s

Buy Merck Stock Because Its Immunotherapy Drug Is a Game-Changer, Analyst Says

Keytruda is a so-called anti-PD(L)1 inhibitor, one of a class of new immunotherapy drugs that uses the patient’s own immune system to fight cancer, and has had a major impact on cancer treatments.

  • Aug. 16, 2019 at 9:14 a.m. ET
  • by Barron’s

A Promising Ebola Drug Isn’t Helping Regeneron Stock. Here’s Why.

An experimental Ebola drug developed by Regeneron Pharmaceuticals has shown promising results. But Wall Street hasn’t rewarded the stock because of it.

  • Aug. 13, 2019 at 11:47 a.m. ET
  • by Barron’s

5 Big Pharma Showdowns to Watch

The drug business can feel like a go-kart race, with big pharmaceutical giants and biotech startups knocking against each other as they scramble to be the first to market with the next big blockbuster.

  • Aug. 12, 2019 at 5:00 a.m. ET
  • by Barron’s

Dow ends Friday trade lower but indexes chipped away at ugly skid that kicked off a wild week

  • Aug. 9, 2019 at 4:45 p.m. ET
  • by Mark DeCambre

Gilead’s HIV drug Biktarvy approved in China

Gilead Sciences Inc.’s drug Biktarvy has been approved for the treatment of HIV-1 in China, the company said Friday. The China National Medical Products Administration approved the drug as a treatment for patients with HIV-1 that isn’t resistant to the integrase inhibitor class of drugs, emtricitabine or tenofovir. Biktarvy received marketing approval from the U.S. Food and Drug Administration and the European Commission in 2018. “Gilead is pleased that people living with HIV in China will now have our newest HIV treatment innovation as a treatment option,” said Diana Brainard, Gilead’s senior vice president of HIV and emerging viruses, in a statement. Gilead reported earnings last week that beat analysts’ expectations. The company’s HIV products continue to be a strong base for the company, with second-quarter HIV drug sales growing to $4 billion from $3.7 billion a year ago. Shares of Gilead have gained 3.6% in the year to date through Thursday, while the S&P 500 has gained 17.2%.

  • Aug. 9, 2019 at 9:00 a.m. ET
  • by Sarah Toy

4 Reasons to Buy Gilead Stock Despite Its Big Sl >The stock is down more than 17% in the trailing 12-month period, but Citigroup has reiterated a Buy rating.

  • Jul. 31, 2019 at 10:45 a.m. ET
  • by Barron’s

Gilead earnings show surprising sales increase amid massive change

  • Jul. 31, 2019 at 6:56 a.m. ET
  • by Jeremy C. Owens

Gilead Sciences Beats Second-Quarter Earnings Expectations

The biotech company, which slightly raised its projected sales for the full fiscal year, attributed its earnings growth to sales of its HIV drugs.

  • Jul. 30, 2019 at 5:05 p.m. ET
  • by Barron’s

Gilead and Amgen will report second-quarter earnings after the closing bell. Here’s what to expect

  • Jul. 30, 2019 at 1:52 p.m. ET
  • by Sarah Toy

Under Armour stock set for worst day in 2 years; Apple, AMD earnings on deck

  • Jul. 30, 2019 at 10:34 a.m. ET
  • by Emily Bary

Gilead Sciences Is a ‘Top Pick.’ Analyst Says the Stock Can Rise 40%.

RBC Capital Markets analyst Brian Abrahams planted a big, flapping flag Monday morning, upgrading Gilead Sciences to Top Pick, from Outperform.

  • Jul. 29, 2019 at 9:29 a.m. ET
  • by Barron’s

Dow Is Inching Higher, While Pfizer and Starbucks Are Falling

Earnings are slim this morning, while U.S.-China trade talks are set to resume Tuesday, followed by what is widely anticipated to be an interest-rate cut from the Federal Reserve on Wednesday.

  • Jul. 29, 2019 at 9:22 a.m. ET
  • by Barron’s

Drugmakers Lobby Hard to Preserve Pricing Power

Worried drugmakers are stepping up efforts to blunt proposals in Washington that they view as some of the most serious threats to their pricing power in recent years.

  • Sep. 24, 2019 at 5:30 a.m. ET
  • on The Wall Street Journal

Louisiana’s Deal for Hepatitis C Drugs May Serve as Model

Louisiana has broadened access to hepatitis C therapies with a payment deal that has been likened to a Netflix subscription.

  • Sep. 13, 2019 at 9:50 a.m. ET
  • on The Wall Street Journal

U.S. Task Force to Recommend W >Adults of a wide range of ages should be screened for hepatitis C, according to a new draft recommendation from the U.S. Preventive Services Task Force that could greatly expand the number of people treated for the disease.

  • Aug. 27, 2019 at 12:45 p.m. ET
  • on The Wall Street Journal

Medicare Moves to Cover Costly Cell Therapies

Medicare and Medicaid will cover an expensive new kind of cancer drug and related services, though the federal government insurance programs won’t pay 100% of the costs, which can approach $1 million a patient.

  • Aug. 7, 2019 at 9:08 p.m. ET
  • on The Wall Street Journal

U.S. Stocks Edge Higher

U.S. stocks edged higher, ending at fresh records after flitting between small advances and losses for much of the trading day.

  • Jul. 15, 2019 at 4:20 p.m. ET
  • on The Wall Street Journal

Stocks to Watch: Circor International, Callon Petroleum, American Airlines, Boeing and More

Circor, Callon Petroleum, American Airlines, Boeing, Gilead Sciences, Facebook and Johnson & Johnson are among Monday’s stocks to watch.

  • Jul. 15, 2019 at 8:48 a.m. ET
  • on The Wall Street Journal

Gilead to Boost Stake in Belgian Biotech Galapagos as Part of $5.1 Billion Deal

Gilead Sciences will pay $5.1 billion to lift its stake in Galapagos and gain rights outside Europe to the Belgian biotechnology company’s treatments in development.

  • Jul. 14, 2019 at 3:22 p.m. ET
  • on The Wall Street Journal

Plan on More Pharma Megamergers

Tough R&D conditions and backlash over high drug prices have put megamergers back on the agenda for biotech and pharma companies desperate for growth.


Gilead sciences stock


Written by admin

Leave a Reply

Your email address will not be published. Required fields are marked *